- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02655939
Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis
Double Blind, Randomized, Multicentre, Placebo Controlled Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis
Reflex plus™ is a unique blend of Collagen Hydrolysate with Rosehip extract. The blend contains individual ingredients which have been widely studied for its effectiveness in osteoarthritis(OA). Collagen hydrolysate is accumulated in the cartilage and helps to repair the OA, related cartilaginous changes. Rosehip works in the anti-inflammatory pathway thus reducing the pain and inflammation of the joint.
The two open-label studies have showed the effectiveness of the investigational product on OA. The 2 studies did not show any specific safety concern to be considered. The study demonstrated the synergistic effect of CH and Rosehip extract from former in-vitro results in the formulation.
The supplement has been manufactured in GMP certified manufacturing units in Germany and India under strict quality control check. Hence, quality of the supplement and batch to batch consistency is well assured.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Mumbai, Maharashtra, India, 400059
- Mukund Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male and Female, aged ≥ 50 yrs and ≤ 70 yrs, with BMI<30.
- WOMAC pain score, between 8-16 on a scale of 0 to 20.
- Diagnosis confirmed of Gonarthrosis, by clinical and radiological means by Jaeger-Wirth score ≥2.
- Females to be included in the study should have reached menopause.
- Subjects willing to stop the restricted supplements and medications prior to inclusion in study and even during the study.
- Subjects using topical applications and rescue medication willing to stop the use 48 hours prior to all assessment.
- Subjects with Fasting blood glucose level ≤ 140 and Systolic blood pressure ≤ 160 mm of Hg and diastolic blood pressure ≤ 100 mm of hg.
- Subjects willing to adhere to protocol and complete subject diary.
- Patient willing and able to provide signed informed consent.
Exclusion Criteria
- Knee pain or functional impairment of the knee joint from causes other than osteoarthritis.
- Peripheral arterial occlusive disease
- Acute meniscus injuries
- Rheumatoid Arthritis
- Infection-associated arthritis
- Coxarthrosis
- Bony injuries of lower extremities(e.g. femoral neck fracture) in the last 12 months
Herniated Spinal Disc
- Any other severe organic and/or systemic diseases (e.g. renal, hepatic, cardiovascular) as per investigator's discretion
- Known allergies and/or sensitivities to ingredients of Reflex Plus™ or rescue medication
- Regular intake of products that may influence the study outcome, e.g.:
Nutritional Supplement such as vitamin supplements Mineral products, protein, amino acid concentrates Chondroprotective agents such as glucosamine sulfate, chondroitin sulfate, gelatin, hyaluronic acid and methylsulfonylmethane.
Fish oil capsules (omega 3 fatty acid capsules)
- Treatment with cartilage protection products in the last 3 months.
- Treatment (oral ingestion and injection) with steroidal and non-steroidal anti-inflammatory drugs with an exception of the following short-acting NSAID: acetylsalicylic acid, diclofenac, ibuprofen, celecoxib; other analgesics e.g. paracetamol, metamizole and phenazone.
- Cortisone treatment within less than 3 weeks prior to study inclusion.
- Intake of Opioid analgesics.
- Intake of anticoagulants of the coumarin type, such as acenocoumarol and phenprocoumon.
- Simultaneous treatment of osteoarthritis of knee with magnetic therapy, shockwave therapy, acupuncture
- Smokers will be excluded from the study. Occasional smokers willing to abstain smoking during the study can be considered.
- History of drug and alcohol abuse.
- Simultaneous participation in another clinical trial or participation in such within the last 6 weeks.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Reflex Plus
Reflex Plus TM, Sachets to be taken once in a day Before breakfast for the study duration
|
Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
|
Placebo Comparator: Placebo
Placebo Sachets to be taken once in a day Before breakfast for the study duration
|
Fructose,Orange flavor and sucralose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction from baseline in total score of WOMAC osteoarthritis index at Week 12.
Time Frame: 12 week for protocol A
|
To study the change in WOMAC index score from Baseline to Week 12 with respect to: Pain, Stiffness, Physical Function .Total WOMAC score 27 we expect a decrease from baseline WOMAC score in the subjects with knee joint pain.
|
12 week for protocol A
|
Reduction from baseline in total score of WOMAC osteoarthritis index at Week 24.
Time Frame: 24 week for protocol B
|
To study the change in WOMAC index score from Baseline to Week 24 with respect to: Pain, Stiffness, Physical Function .Total WOMAC score 27 we expect a decrease from baseline WOMAC score in the subjects with knee joint pain.
|
24 week for protocol B
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in anti-inflammatory markers measured as change from baseline in Serum C reactive protein (CRP) at Week 12.
Time Frame: 12 week for protocol A
|
To study the change on anti-inflammatory markers, Serum C reactive protein (CRP) measured from baseline to Week 12. C- reactive protein Normal Range is < 5.0 mg/dl which is expected to be raised in subjects with Osteoarthritis. |
12 week for protocol A
|
Reduction of anti-inflammatory markers measured as change from baseline in Serum C reactive protein (CRP) at Week 24.
Time Frame: 24 week for protocol B
|
To study the change on anti-inflammatory markers, Serum C reactive protein (CRP) measured from baseline to Week 24. C- reactive protein Normal Range is < 5.0 mg/dl which is expected to be raised in subjects with Osteoarthritis. |
24 week for protocol B
|
Increase in joint flexibility measured as change from baseline in axis and range of motion as assess by goniometry at Week 12.baseline in axis and range of motion as assess by goniometry at Week 12
Time Frame: 12 week for protocol A
|
To study the change on joint flexibility measured as change from baseline by goniometry to Week 12. Joint Inspection Joint Palpation,Impaired Movement,Axis of Joint,Range of Motion We expect change in range of motion as assessed by goniometry |
12 week for protocol A
|
Increase in joint flexibility measured as change from baseline in axis and range of motion as assess by goniometry at Week 12.baseline in axis and range of motion as assess by goniometry at Week 24
Time Frame: 24 week for protocol B
|
To study the change on joint flexibility measured as change from baseline by goniometry to Week 24. Joint Inspection Joint Palpation,Impaired Movement,Axis of Joint,Range of Motion To study the change in MRI for index joint as change from baseline to Week 24.we expect change in range of motion as assessed by goniometry Joint Inspection Joint Palpation,Impaired Movement,Axis of Joint,Range of Motion To study the change in MRI for index joint as change from baseline to Week 24.we expect change in range of motion as assesed by goinometry |
24 week for protocol B
|
Improvement in structure cartilage of knee joint measured as change in MRI analysis from baseline to Week 24.
Time Frame: 24 weeks for protocol B
|
To study the effect of Reflex Plus™ on structure of knee joint measured as change in MRI analysis from baseline to Week 24.
|
24 weeks for protocol B
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Dr Sachin Dighe, B.A.M.S., sachin.d@vediclifesciences.com
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FZ/150603/RFX+/OA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis
-
Sanford HealthActive, not recruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder Osteoarthritis | Ankle Osteoarthritis | Wrist OsteoarthritisUnited States
-
University of EdinburghHospital for Special Surgery, New YorkRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited Kingdom
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
University of California, San FranciscoStanford University; Robert Wood Johnson FoundationCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
-
University of VermontCompletedOsteoarthritis of Knee | Osteoarthritis Of HipUnited States
-
Hospital for Special Surgery, New YorkRoyal Infirmary of EdinburghRecruitingKnee Osteoarthritis | Hip Osteoarthritis | Shoulder OsteoarthritisUnited States, United Kingdom
-
Ottawa Hospital Research InstituteNot yet recruitingKnee Osteoarthritis | Hip Osteoarthritis
-
University Hospital, LilleCompleted
-
Massachusetts General HospitalNewton-Wellesley Hospital; The New England Baptist HospitalCompletedKnee Osteoarthritis | Hip OsteoarthritisUnited States
Clinical Trials on Reflex Plus
-
Cambridge University Hospitals NHS Foundation TrustCompletedChildhood CataractUnited Kingdom
-
Istanbul Physical Medicine Rehabilitation Training...CompletedSpinal Cord InjuriesTurkey
-
Beijing Tiantan HospitalRecruitingMyocardial Injury | Trigeminal Cardiac ReflexChina
-
Istanbul Physical Medicine Rehabilitation Training...CompletedMuscle Hypertonia | Reflex, AbnormalTurkey
-
Danish Headache CenterRecruitingTrigeminal NeuralgiaDenmark
-
Hospices Civils de LyonRecruiting
-
Burke Medical Research InstituteRecruitingCerebral Palsy | Spastic Cerebral PalsyUnited States
-
NUMEN FoundationCompletedNeurological DisorderSpain
-
University Hospital, Clermont-FerrandService de pharmacologie et toxicologie cliniques, Hôpitaux Universitaire... and other collaboratorsCompleted
-
Benno Rehberg-KlugNot yet recruitingLow Back Pain | Chronic Pain | Neck Pain